Cancer pharmacoprevention: Targeting polyamine metabolism to manage risk factors for colon cancer.

Gerner, Eugene W; Bruckheimer, Elizabeth; Cohen, Alfred

Gerner, Eugene W; Bruckheimer, Elizabeth; Cohen, Alfred.

Affiliation

Gerner EW; From Cancer Prevention Pharmaceuticals, Tucson, Arizona 85718 and egerner@canprevent.com.
Bruckheimer E; the Department of Cell and Molecular Medicine, University of Arizona, Tucson, Arizona 85711.
Cohen A; From Cancer Prevention Pharmaceuticals, Tucson, Arizona 85718 and.

J Biol Chem ; 293(48): 18770-18778, 2018 11 30.

Article in En | MEDLINE | ID: mdl-30355737

Subject(s)

Colonic Neoplasms/prevention & control; Polyamines/metabolism; Animals; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage; Chemoprevention; Colonic Neoplasms/metabolism; Eflornithine/administration & dosage; Humans

Key words

DFMO; GI tract; NSAID; Wnt signaling; adenomatous polyposis; anticancer drug; cancer chemoprevention; colon cancer; molecular pharmacology; polyamine

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polyamines / Colonic Neoplasms Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: J Biol Chem Year: 2018 Document type: Article

Fulltext

XML

PubMed Links

Search on Google